| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a13 |
KRAS_mut |
1526 |
1 |
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
116 |
759 |
1.61 |
1.86 |
0.673 |
-1.18 |
0.72 . |
0.71 . |
0.84 . |
1.1e-10 |
9.33e-64 |
1.62e-01 |
0.00014 |
a22 |
KRAS_mut |
1498 |
1 |
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
121 |
797 |
1.39 |
1.8 |
0.627 |
-1.17 |
0.69 . |
0.68 . |
0.78 . |
5.44e-10 |
1.34e-55 |
5.9e-02 |
0.00041 |
a29 |
KRAS_mut |
1060 |
1 |
1 |
PD-0325901 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
107 |
731 |
-1.386, 0.693 |
-0.937 |
-2.18 |
-1.24 |
0.71 . |
0.7 . |
0.77 . |
5.99e-09 |
6.16e-47 |
3.13e-02 |
0.0034 |
a38 |
KRAS_mut |
1014 |
1 |
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
106 |
731 |
1.61 |
1.69 |
0.454 |
-1.23 |
0.7 . |
0.69 . |
0.79 . |
5.04e-08 |
5.44e-52 |
1.02e-01 |
0.022 |
a65 |
KRAS_mut |
1015 |
1 |
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
109 |
727 |
2.3 |
2.35 |
1.56 |
-0.783 |
0.54 . |
0.53 . |
0.61 . |
2.4e-06 |
1.29e-38 |
2.59e-02 |
0.6 |
a74 |
KRAS_mut |
1372 |
1 |
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
112 |
781 |
0 |
-0.828 |
-2.47 |
-1.64 |
0.67 . |
0.66 . |
0.76 . |
3.06e-06 |
1.03e-62 |
2.17e-01 |
0.68 |
a255 |
KRAS_mut |
1047 |
1 |
1 |
Nutlin-3a |
MDM2 |
108 |
738 |
2.08, 1.39 |
3.53 |
3.53 |
0.00118 |
0.00087 |
0.00087 |
0.00083 |
1.59e-04 |
8.56e-32 |
6.36e-02 |
10 |
